Variables
Total cohort (n=18)
Hypoinflammatory low viral load (n=8, 61.5%)
Hyperinflammatory (n=2, 15.4%)
Hypoinflammatory high viral load (n=3, 23.1%)
Age, mean ± SD, years 68 ± 8 69 ± 7.8 64 ± 15.6 67 ± 6
Male Gender 50% (9/18) 37.5% (3/8) 100% (2/2) 0 (0/3)
African American race 16.7% (3/18) 12.5% (1/8) 50% (1/2) 33.3% (1/3)
Immunosuppression 33.3% (6/18) 37.5% (3/8) 50% (1/2) 33.3% (1/3)
Body mass index 33.8 ± 12.3 28.9 ± 4.8 33.6 ± 16.5 44.6 ± 24.6
Diabetes mellitus 77.8% (14/18) 75% (6/8) 50% (1/2) 100% (3/3)
Days of intubation prior to BAL 3.6 ± 3.6 3.6 ± 2.1 4 ± 4.2 1.7 ± 1.1
Days from symptoms to BAL, days 13.6 ± 7.8 14.8 ± 7.6 12 ± 4.2 14 ±7
Dexamethasone prior to BAL 100% 100% 100% 100%
Tocilizumab prior to BAL 0 0 50% (1/1) 0
Remdesivir prior to BAL 55.6% (10/18) 62.5% (5/8) 50% (1/1) 33% (1/3)
Max temperature*, mean ± SD, 0C 37.7 ±1.1 37.7 ±0.8 37.8 ±1.7 37.9 ±1.9
Vasopressors* 72.2% (13/18) 75% (6/8) 100% (2/2) 33% (1/3)
Min PaO2/FiO2* 161.4 ± 93.2 153.8 ± 121.1 102.5 ± 20.6 200.5 ± 110.5
CRP*, mean ±SD, mg/L 155.2 ± 117.1 105.6 ± 79 147.9 ± 81.7 151.3 ± 50.8
Max WBC*, mean ± SD, cells/µL 13.3 ± 6.3 12.5 ± 5.8 12.8 ±4.1 12.7 ± 6.1
Min lymphocyte count*, mean ± SD cells/µL 0.7 ± 0.4 0.6 ± 0.3 0.9 ± 1.1 0.5 ± 0.1
BAL neutrophil % 38.5 ± 29.8 22.8 ± 23.7 43 ± 41 38
BAL lymphocyte % 8.4 ± 8.7 9.2 ± 7.7 3.5 ± 2.1 28
Ct value, mean ± SD 22 ± 6.5 26.6 ± 2.6 20 ± 1.1 14.4 ± 1.2
Ventilator- free days, mean ±SD, days 1.8 ± 2.9 1.6 ± 3.1 1.5 ± 2.1 1.3 ± 2.3
Length of stay, mean ± SD, days 31.1 ± 15.6 28 ± 11.4 51.5 ± 3.5 18.7 ± 14.4
Mortality 66.7% (12/18) 75% (6/8) 50% (1/2) 100% (3/3)